Back to Search Start Over

Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial.

Authors :
Kallas, Esper G.
Grunenberg, Nicole A.
Yu, Chenchen
Manso, Bryce
Pantaleo, Giuseppe
Casapia, Martin
Baden, Lindsey R.
Valencia, Javier
Sobieszczyk, Magdalena
Van Tieu, Hong
Allen, Mary
Hural, John
Graham, Barney S.
Kublin, James
Gilbert, Peter B.
Corey, Lawrence
Goepfert, Paul A.
McElrath, M. Juliana
Johnson, R. Paul
Huang, Yunda
Source :
Science Translational Medicine; 11/20/2019, Vol. 11 Issue 519, p1-10, 10p
Publication Year :
2019

Abstract

Troublesome T cells: Many HIV vaccines aim to generate robust T cell responses, but two new studies show that this is not always straightforward. Chamcha et al. analyzed data from several nonhuman primate vaccine studies with SIV/SHIV challenges and discovered that achieving a certain threshold of vaccine-induced IFN-γ<superscript>+</superscript> CD4 T cells lowered vaccine efficacy, possibly by providing target cells for the virus. Kallas et al. vaccinated people with HIV Gag/Pol alone or with Env to see whether antigenic competition could interfere with CD4 T cell responses; lower responses to Gag/Pol were detected when Env was also administered, indicating that including multiple antigens in a vaccine may preclude maximal T cell responses. Together, these studies highlight how we must tread carefully on the path to an effective HIV vaccine. T cell responses have been implicated in reduced risk of HIV acquisition in uninfected persons and control of viral replication in HIV-infected individuals. HIV Gag-specific T cells have been predominantly associated with post-infection control, whereas Env antigens are the target for protective antibodies; therefore, inclusion of both antigens is common in HIV vaccine design. However, inclusion of multiple antigens may provoke antigenic competition, reducing the potential effectiveness of the vaccine. HVTN 084 was a randomized, multicenter, double-blind phase 1 trial to investigate whether adding Env to a Gag/Pol vaccine decreases the magnitude or breadth of Gag/Pol-specific T cell responses. Fifty volunteers each received one intramuscular injection of 1 × 10<superscript>10</superscript> particle units (PU) of rAd5 Gag/Pol and EnvA/B/C (3:1:1:1 mixture) or 5 × 10<superscript>9</superscript> PU of rAd5 Gag/Pol. CD4<superscript>+</superscript> T cell responses to Gag/Pol measured 4 weeks after vaccination by cytokine expression were significantly higher in the group vaccinated without Env, whereas CD8<superscript>+</superscript> T cell responses did not differ significantly between the two groups. Mapping of individual epitopes revealed greater breadth of the Gag/Pol-specific T cell response in the absence of Env compared to Env coimmunization. Addition of an Env component to a Gag/Pol vaccine led to reduced Gag/Pol CD4<superscript>+</superscript> T cell response rate and magnitude as well as reduced epitope breadth, confirming the presence of antigenic competition. Therefore, T cell–based vaccine strategies should aim at choosing a minimalist set of antigens to reduce interference of individual vaccine components with the induction of the maximally achievable immune response. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
19466234
Volume :
11
Issue :
519
Database :
Complementary Index
Journal :
Science Translational Medicine
Publication Type :
Academic Journal
Accession number :
139725313
Full Text :
https://doi.org/10.1126/scitranslmed.aaw1673